PURPOSE: This workshop will focus on the practical use of health technology assessment for assessing developments in the rapidly growing area of precision medicine. Workshop participants will become familiar with a decision analytic framework and technical aspects of modeling suitable for existing diagnostics as well as approaches for prospective assessment of the value of future test development (early HTA), as part of skills needed to critically appraise the value of innovations in this field.  DESCRIPTION: This workshop will combine broad context-setting and discussion of practical challenges and implications with hands-on technical demonstrations using two key examples from different settings (pharmacogenetics/warfarin) and (imaging/stroke) to illustrate the application of HTA in precision medicine. Dr Yoong will first provide a brief overview of key recent developments in the field of precision medicine, illustrating a range of implications for clinical practice and policy decision making. Using data from published literature, Dr Wee will demonstrate the use of Markov modeling using TreeAge in evaluating the use of an existing pharmacogenetic test to individualize warfarin doses. Audience members will be interactively involved in model construction and design of sensitivity analyses, and will also be encouraged to critically discuss the results and implications for adoption and regulation.  Dr Redekop will then demonstrate the value of early HTA during test development, using imaging technologies for stroke patients as an example. Audience members will participate by suggesting scenarios for the analysis and discussing potential implications for researchers, test developers and funding agencies. Finally, the audience will be invited to share experiences and perspectives on the types and uses of HTA that are likely to be most valuable as the field of precision medicine evolves.